Bristol Myers Squibb (BMY): A pullback inside a longer uptrend

not supported. Registered 2026-10-03.

The result did not improve on the baseline after the cost allowance in every period. The annual comparison did not pass the 512-trial correction (adjusted p=1.0000).

Higher 7-calendar-day company returns minus the S&P 500 price return on identical dates; 0.4 percentage-point round-trip cost allowance. Non-overlapping windows; period-end windows excluded. Baseline: eligible dates in the same period, also measured relative to the market. Positive median market-relative returns after costs are also required in all three periods. Annual sign comparisons use a fixed 512-trial Bonferroni correction. Discovery before 2010, validation 2010–2017, confirmation 2018 through September 2026. Conditional association, not a risk-adjusted alpha estimate or an executable trading strategy. Historical selection remains exploratory; forward observations start after publication.

Open the evidence, sources and forward ledger

Conditions

• $19393.ret_30d:lt:-5
• $19393.sma200_gap:gt:0

Research history

• 2026-10-03T00:02:41.681Z — The conditions match the available data for 2026-10-01.
• 2026-10-03T00:02:41.624Z — The result did not improve on the baseline after the cost allowance in every period.
• 2026-10-03T00:01:33.612Z — Investigation registered. Its conditions and test periods are fixed.